Key Takeaways
- Domestic growth held up, but the real story is the gap: Formulation revenue grew 6% against a high COVID base, yet like-to-like growth was 11-12% and secondary sales per IQVIA grew 13.5%. The gap came from a 1-1.5 month inventory overhang in the trade, which management expects to normalize in Q3.
- Gross margin took a 2% hit, and relief is conditional: Raw and packing material cost increases of ₹23 Crores outpaced price hikes, dragging gross margin down YoY. Management sees stabilization ahead but is explicit that margin will not expand unless raw material and packing material prices correct.
- Exports quadrupled, and the company says it is sustainable: US supplies were 4x the prior-year six-month level, pushing export formulations to ₹75 Cr in Q2. Management confirmed no one-offs and expects the run-rate to hold.
- A deliberate portfolio shift is underway, away from antibiotics and ORS: New divisions in derma (Zocon, ~500 reps), nutraceuticals (Nuritrica, targeting ₹68-70 Cr this year), and cardio-diabeto are the visible bets to reduce seasonality and concentration risk.
- What to watch next quarter: Whether the primary-secondary sales gap closes as guided, whether gross margin stabilizes or raw material costs stay elevated, and any update on the Waluj ophthalmic line timeline, now pushed to ~2 years for US commercialization.
The Primary-Secondary Sales Gap
- The gap is inventory, not demand weakness: Reported revenue growth of 6.4% lagged IQVIA secondary sales growth of 13.5% because last year's COVID upsurge left the trade holding 1 to 1.5 months of excess stock. This phenomenon was visible across other companies as well.
- Prescription data confirms underlying momentum: FDC's prescription growth was 51% in H1 versus 47% for the IPM, a reversal from last year when secondary sales were high but prescriptions were suppressed by COVID restrictions.
- Convergence expected in Q3: Management stated that secondary and tertiary stock levels are now stabilizing and that AIOCD-reported numbers and internal reported numbers should come very close to each other in Q3.
Tikkha: "Our endeavour over a period of time is to mitigate this seasonality part of it by diversifying our portfolio and create newer avenues for our existing brands in the off season scenario."
Gross Margin: Pressure, Price Hikes, and the Raw Material Overhang
- The 2% drag decomposed: Incremental gross margin of ₹21 Cr in Q2 versus Q2 last year comprised roughly ₹30 Cr from price increases (scheduled and non-scheduled), offset by a ₹23 Cr raw material and packing cost increase, plus a ₹15 Cr positive contribution from export formulations. The net effect was a margin drag close to 2%.
- Price hikes are flowing through, but slowly: A 10-11% price hike on scheduled formulations was implemented, and the full benefit started flowing through only from Q2 onward. Management expects the full impact to be available in Q3 and Q4, leading to stabilization.
- Sequential improvement, but no expansion without a raw material correction: Gross margin improved about 1% QoQ from Q1 to Q2 as inflation stabilized and supply chains normalized. However, management was explicit that gross margin will not increase further unless there is a drop or correction in raw material and packing material prices.
- The raw material math is unfavorable: The percentage increase in raw material prices is much higher than the sales price increase available, so the absolute cost impact overwhelms the price relief.
Jain: "Unless we see a drop or correction in the raw material and the packing material prices."
Export Surge and the US Ophthalmic Bet
- Exports hit ₹75 Cr in Q2, a 68% YoY jump: The growth was largely on account of increased supplies to US customers, which were four times higher than the last year six-month period, supported by other geographies. Management confirmed the growth contains no one-offs and should be sustainable.
- No new US launches this fiscal year: No new ophthalmology product launches are scheduled for the remainder of FY23; one product is awaited but not yet scheduled. Existing products will continue to be sold.
- Waluj plant timeline has slipped materially: The fourth ophthalmic line project is delayed. Equipment shift is expected around January 2, with installation taking about one month. Qualification and US FDA approvals are expected to take approximately 18 months from installation, pushing commercial production for the US business to roughly two years out.
- International ambition is large: Management set a target of ₹450-500 Cr in international formulation revenue by the end of FY2025, with heavy margins.
Portfolio Diversification and the Seasonality Problem
- H1 is structurally heavier than H2: Q1 and Q2 are peak quarters driven by ORS, energy drinks, and antibiotics. Q3 is the lean season because neither category has a seasonal tailwind, and antibiotic sales drop across the board in H2. Q4 gets some support from an Electral push.
- New divisions are the answer to seasonality: The company has launched or scaled divisions in derma (Zocon, ~550 reps), nutraceuticals (Nuritrica), and cardio-diabeto, none of which carry the same seasonality as antibiotics and ORS. Over the last two years, seasonality has been successfully mitigated in two quarters; only Q3 still shows a fall in overall volumes.
- Nuritrica is scaling fast: The nutraceutical division, consolidated two years back, has grown from roughly ₹32 Cr to an expected ₹68-70 Cr this year. Management is looking at a ₹100 Cr basket from the nutraceutical portfolio, though it called that target very early.
- Lumina division underperformance is a COVID hangover: The Lumina division, which carries Azithromycin, is in a non-performance mode, mainly attributed to the Azithromycin upsurge last year during COVID.
- Seasonality narrowing has a natural limit: Management acknowledged that beyond a point, narrowing is not possible because the Q3 antibiotic market is always lean. The percentage deviation may remain constant even if all quarters grow equally.
Tikkha: "If I was to do Rs.100 sale that percentage will remain the same because you try to grow in each quarter equally looking at the opportunity which is available so that percentage might not change but yes we are trying to get some significance out of each quarter and each month for some of our products..."
Costs, Capex, and Working Capital
- Opex-to-sales rose ~350 bps in H1: The increase was mainly driven by sales and marketing expenses from launching the new Zocon division, including travel allowances for the ~550 people added, plus roughly ₹10 Cr in advance procurement of sales and marketing materials that is expected to rationalize in Q3 and Q4.
- Employee cost held at 20% of revenue: The ratio was marginally lower YoY due to the increased revenue base, but absolute costs rose because of the new division launch and annual appraisals.
- Capex is running heavy and will spill over: Total H1 capex was roughly ₹120 Cr, split between the corporate office including R&D (~₹70 Cr) and operational capex at Waluj and Sinnar plants (~₹40-50 Cr). All three projects are ongoing and capex will continue, potentially spilling into the next financial year.
- Working capital days rose from 59 to ~67 days: The increase came from two sources: significantly higher raw material and packing material prices locking up more funds in inventory, and a higher export component in the trailing twelve months, where credit periods are longer than domestic. Management stated the cycle is very close to peak and no further increase is expected.
Jain: "It is very close to peak, I do not think so there will be any further increase on our working capital cycle."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Primary-secondary sales gap closure | AIOCD and internal growth numbers to converge as COVID-era trade inventory stabilizes | Q3 FY23 |
| Gross margin stabilization | Full benefit of scheduled price hikes to flow through; stabilization expected, but no expansion unless raw material prices correct | Q3 and Q4 FY23 |
| Opex rationalization | Advance procurement of sales and marketing materials (~₹10 Cr impact in H1) to normalize | Q3 and Q4 FY23 |
| Waluj plant US commercialization | Equipment shift ~Jan 2; installation ~1 month; US FDA approvals ~18 months from commissioning; commercial production thereafter | ~2 years |
| International formulation revenue target | ₹450-500 Cr with heavy margins | By end of FY2025 |
| Overall company CAGR target | At least 15-18% topline and bottom-line CAGR | Next 3-5 years |
| Nutraceutical portfolio scale | Confident of closing current year at ₹68-70 Cr; ₹100 Cr basket as aspiration | FY23 / medium term |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue growth | 12% YoY; 11% for H1 FY23 |
| Domestic formulation revenue growth | 6% YoY; like-to-like growth would have been 11–12% excluding prior-year COVID therapy products |
| Export formulation revenue growth | 68% YoY for Q2; 48% for H1 |
| Export API revenue growth | 31% YoY for Q2; 28% for H1 |
| EBITDA margin | 18%, down from prior year |
| Gross margin impact from raw and packing material | 2% decline YoY, absolute impact of ₹23 cr for the quarter |
| Gross margin QoQ improvement | ~1% improvement from Q1 FY23 to Q2 FY23 |
| Employee cost | 20% of revenue, marginally lower YoY owing to increased revenue base |
| Export incentive recorded in H1 | ₹32 cr |
| Secondary sales growth (IQVIA) | 13.5% YoY during Q2 FY23 |
| MAT volume growth | 5.9% |
| MAT price growth | 5.3% |
| MAT new product growth | 1.4% |
| PCPM (fee for productivity) | ~₹3.5 lakh per MR per month, largely flat YoY |
| MR count | ~3,600; 550 added for new derma division |
| Domestic sales under price control (NLEM) | ~46% |
| Electral MAT milestone | Crossed ₹350 cr on MAT September 2022 basis |
| Electral market share | 74% |
| Zifi market share (MAT) | 24.7%, up from 23.9% in September 2020 |
| Enerzal market share | 42%+ |
| Zifi CV market share | 49.3% |
| Zifi O market share | 14.6% |
| H1 brand growth: Electral | 30.5% |
| H1 brand growth: Enerzal | 37.9% |
| H1 brand growth: Zifi | 11.1% |
| H1 brand growth: Vitcofol | 14.6% |
| H1 brand growth: Zifi CV | 15.7% |
| Nutraceutical division (Nutritica) expected full-year volume | ₹68–70 cr, up from ~₹32 cr two years prior |
| International formulation expected full-year revenue | ₹200–220 cr |
| International business target by end of FY2025 | ₹450–500 cr with heavy margins |
| Overall company CAGR target (next 3–5 years) | 15–18% for both topline and bottom line |
| Q2 FY23 exports topline | ₹75 cr |
| Working capital days | ~67 days on trailing 12-month basis, up from 59 days in FY22 |
| Price increase benefit for H1 | ~₹40–45 cr, effective from ~May onwards; net benefit closer to ₹30 cr (per an analyst's math) |
| Incremental gross margin Q2 FY23 vs Q2 FY22 | ₹21 cr positive, with ~₹30 cr from price increases, ~₹15 cr from export formulation, offset by ~₹23 cr raw/packing material cost increase |